⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 1, 2022Alimentary Pharmacology & TherapeuticsOpen Access

Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom

View Full Paper

Ask AI

Bookmark

Share

Abstract

We estimate annual direct healthcare costs of IBS of between £1.3 and £2 billion in the United Kingdom.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Goodoory et al. (2022) studied this question.

synapsesocial.com/papers/69d760bb5f9a1dad53490009 https://doi.org/10.1111/apt.16939

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The economic impact of irritable bowel syndromeSystematic Review · 2003 · 195 citations
2Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis.Meta-Analysis · 2019 · 79 citations
3Rational investigations in irritable bowel syndromeOriginal Research · 2019 · 20 citations
4Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary careDiagnostic Study · 2020 · 85 citations
5Racial disparity in healthcare utilization among patients with Irritable Bowel Syndrome: results from a multicenter cohortRetrospective Study · 2020 · 30 citations